{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"TEAE related to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"TEAE(CTCAE≥3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"TEAE related to treatment(CTCAE≥3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Safety evaluations will be based on scheduled physical examinations, Eastern Cooperative Oncology Group(ECOG) scores, vital signs (blood pressure, heart rate) and clinical laboratory tests.","groups":[{"description":"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\n\nPAD Followed by ASCT: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)\n\nDrug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)\n\nDrug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.","id":"OG000","title":"PAD Followed by ASCT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Starting with informed consent signature through study completion, an average of 1 year","title":"Safety Evaluation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}